Sumeet Salaniwal's Research Focus
As Director of Informatics at the Conrad Prebys Center for Chemical Genomics at SBP, Dr. Sumeet Salaniwal’s primary responsibility is to oversee, direct, and integrate all activities within the Informatics group to provide and support state-of-the-art aligned and integrated cheminformatics, bioinformatics, and computational modeling solutions to discovery teams. He provides strategic planning and collaboratively leads new scientific endeavors to create and implement robust and efficient informatics solutions for Assay Development, High-Throughput/High Content Screening, Medicinal Chemistry, Pharmacology, and Compound Management teams.
Sumeet Salaniwal's Bio
Dr. Sumeet Salaniwal has over 15 years of experience in computational drug discovery with extensive experience in formulating and executing on innovative informatics ideas and strategies that enable more efficient advancement and identification of drug discovery projects through application of advanced computational modeling and scientific informatics approaches for hit identification, hit validation, hit-to-lead optimization, lead optimization, and ADME/Tox profiling. Dr. Salaniwal has broad experience in supporting HTS/HCS screening, hit-to-lead and lead optimization efforts for multiple targets, including oncology, diabetes, infectious diseases, inflammation, and CNS indications.
Prior to joining SBP in 2011, Dr. Salaniwal developed high-content data analysis tools and an inventory management system at BrainCells Inc. to support preclinical development of a drug candidate for cognitive dysfunction and depression. Before that, he was a Lead Scientist at Biovia (formerly Accelrys Inc.) where he developed and applied novel computational techniques for lead optimization, SAR analysis, and de-novo ligand design across a wide range of drug targets in collaboration with scientific leads at major pharmaceutical and biotech companies. Dr. Salaniwal received his Ph.D. in Chemical Engineering from the University of Tennessee, and performed post-doctoral training in the Structural Biology and Computational Chemistry group at Wyeth Pharmaceuticals (now Pfizer) where his contributions led to the advancement of several discovery programs in women’s health.